IAM
VRTX icon

Impact Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Impact Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$6.19M Sell
12,770
-120
-0.9% -$55.9K 2.43% 14
2024
Q4 		$5.19M Sell
12,890
-65
-0.5% -$30.1K 2.05% 20
2024
Q3 		$6.03M Buy
+12,955
New +$6.22M 2.32% 21

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Impact Asset Management's VRTX Position: Q1 2025 in Review

Impact Asset Management reduced its Vertex Pharmaceuticals (VRTX) stake by 0.93% in Q1 2025, selling an estimated $55.9K and leaving 12,770 shares worth $6.19M. The position accounts for 2.43% of the portfolio, ranked #14.

Impact Asset Management first reported a position in VRTX in Q3 2024 and has held it in 3 quarters since. 1,612 funds tracked by Wall St. Rank hold VRTX as of Q1 2025.

  • Impact Asset Management held 12,770 shares of Vertex Pharmaceuticals worth $6.19M as of Q1 2025.
  • Impact Asset Management sold 120 Vertex Pharmaceuticals shares in Q1 2025, an estimated $55.9K.
  • Vertex Pharmaceuticals made up 2.43% of Impact Asset Management's portfolio in Q1 2025, its #14 holding.
  • Impact Asset Management first reported a position in Vertex Pharmaceuticals in Q3 2024 and has held it in 3 quarters since.
  • 1,612 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2025.

Based on Impact Asset Management's 13F filing for Q1 2025, filed 14 Aug 2025.